Clementina Maria Galluzzo

List of Publications by Year
in descending order

42 papers	640 citations	623188 14 h-index	610482 24 g-index
42 all docs	42 docs citations	42 times ranked	1143 citing authors

#	Article	IF	Citations
1	Novel Bifunctional Quinolonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors:â€‰ Design, Synthesis, Biological Activities, and Mechanism of Action. Journal of Medicinal Chemistry, 2006, 49, 1939-1945.	2.9	82
2	Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA. Journal of Clinical Virology, 2009, 46, 367-370.	1.6	54
3	Novel Quinolinonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, and Biological Activities. Journal of Medicinal Chemistry, 2008, 51, 4744-4750.	2.9	45
4	Antiretroviral Prophylaxis for Breastfeeding Transmission in Malawi: Drug Concentrations, Virological Efficacy and Safety. Antiviral Therapy, 2012, 17, 1511-1519.	0.6	37
5	Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. Journal of Antimicrobial Chemotherapy, 2016, 71, 1027-1030.	1.3	32
6	Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing. Journal of Clinical Microbiology, 2003, 41, 1760-1762.	1.8	28
7	Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. PLoS ONE, 2014, 9, e109791.	1.1	26
8	Quality of life outcomes of combination zidovudineâ€“didanosineâ€“nevirapine and zidovudineâ€“didanosine for antiretroviral-naive advanced HIV-infected patients. Aids, 2000, 14, 2567-2574.	1.0	24
9	HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology, 2007, 4, 17.	0.9	20
10	Discordant response to antiretroviral therapy. Aids, 2002, 16, 1877-1885.	1.0	18
11	Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. Aids, 2003, 17, 1570-1572.	1.0	18
12	Development of a Human Immunodeficiency Virus Vector-Based, Single-Cycle Assay for Evaluation of Anti-Integrase Compounds. Antimicrobial Agents and Chemotherapy, 2006, 50, 3407-3417.	1.4	18
13	Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. Journal of Virological Methods, 2010, 168, 272-276.	1.0	15
14	High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic Analysis. Journal of Clinical Microbiology, 2003, 41, 3007-3012.	1.8	14
15	Amniocentesis and chorionic villus sampling in HIVâ€infected pregnant women: a multicentre case series. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1218-1223.	1.1	14
16	Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment1. Antiviral Research, 2000, 47, 189-198.	1.9	13
17	Short Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 816-818.	0.5	13
18	Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of motherâ€toâ€infant transmission in Malawi. Journal of Medical Virology, 2012, 84, 1553-1557.	2.5	13

#	Article	IF	Citations
19	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. Journal of Antimicrobial Chemotherapy, 2014, 69, 1377-1384.	1.3	13
20	The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. HIV Medicine, 2009, 10, 477-481.	1.0	11
21	Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. Aids, 2007, 21, 2360-2362.	1.0	10
22	Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 1479-1485.	1.3	10
23	Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis. HIV Clinical Trials, 2016, 17, 49-54.	2.0	10
24	A Randomized Trial Comparing the Introduction of Ritonavir or Indinavir in 1251 Nucleoside-Experienced Patients with Advanced HIV Infection. AIDS Research and Human Retroviruses, 2000, 16, 1809-1820.	0.5	9
25	Comparison of HIV Type 1 Sequences from Plasma, Cell-Free Breast Milk, and Cell-Associated Breast Milk Viral Populations in Treated and Untreated Women in Mozambique. AIDS Research and Human Retroviruses, 2009, 25, 707-711.	0.5	9
26	Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens. AIDS Research and Human Retroviruses, 2015, 31, 71-77.	0.5	9
27	Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. AIDS Research and Human Retroviruses, 2016, 32, 737-742.	0.5	9
28	Antiretroviral Resistance Mutations in Untreated Pregnant Women with HIV Infection in Uganda and Rwanda. AIDS Research and Human Retroviruses, 2007, 23, 1449-1451.	0.5	8
29	Rate, correlates and outcomes of repeat pregnancy in HIV-infected women. HIV Medicine, 2017, 18, 440-443.	1.0	8
30	Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial. AIDS Research and Human Retroviruses, 2010, 26, 541-545.	0.5	7
31	HIVâ€1 DNA dynamics and variations in HIVâ€1 DNA protease and reverse transcriptase sequences in multidrugâ€resistant patients during successful raltegravirâ€based therapy. Journal of Medical Virology, 2016, 88, 2115-2124.	2.5	7
32	The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. Cytokine, 2012, 57, 54-60.	1.4	6
33	Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. Infectious Diseases, 2016, 48, 317-321.	1.4	6
34	Levels of bone markers in a population of infants exposedin uteroand during breastfeeding to tenofovir within an Option B+ programme in Malawi. Journal of Antimicrobial Chemotherapy, 2016, 71, 3206-3211.	1.3	5
35	Viral Sequence Analysis of HIV-Positive Women and Their Infected Children: Insight on the Timing of Infection and on the Transmission Network. AIDS Research and Human Retroviruses, 2014, 30, 1010-1015.	0.5	4
36	Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. Journal of Antimicrobial Chemotherapy, 2015, 70, 2881-2884.	1.3	4

#	Article	IF	Citations
37	Deficit of IgG2 in HIV-positive pregnant women is responsible of inadequate IgG2 levels in their HIV-uninfected children in Malawi. Medical Microbiology and Immunology, 2018, 207, 175-182.	2.6	3
38	Effects of Raltegravir on 2-Long Terminal Repeat Circle Junctions in HIV Type 1 Viremic and Aviremic Patients. AIDS Research and Human Retroviruses, 2013, 29, 1365-1369.	0.5	2
39	Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi. Journal of Antimicrobial Chemotherapy, 2014, 69, 749-752.	1.3	2
40	Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV. Clinical Microbiology and Infection, 2016, 22, 818-820.	2.8	2
41	Anti-Streptococcus pneumoniae and rotavirus IgG levels in HIV-positive women do not correlate with maternal status and infant morbidity and mortality. Journal of Medical Microbiology, 2015, 64, 795-797.	0.7	2
42	Laboratory confirmation of clinically diagnosed malaria in a cohort of HIV-infected mothers and their children in Malawi. Journal of Tropical Pediatrics, 2015, 61, 222-225.	0.7	0